Medicure Inc. (MPH.V)
CAD 0.89
(14.1%)
CAD 0.89
(14.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.27 Million CAD | -60.89% |
| 2022 | 3.44 Million CAD | 30.88% |
| 2021 | 2.38 Million CAD | 156.96% |
| 2020 | -4.04 Million CAD | 48.73% |
| 2019 | -17.71 Million CAD | -557.53% |
| 2018 | 5.14 Million CAD | -111.31% |
| 2017 | 2.62 Million CAD | 74.25% |
| 2016 | 5.43 Million CAD | 319.18% |
| 2015 | 2.34 Million CAD | -12.67% |
| 2014 | 3.2 Million CAD | 397.55% |
| 2013 | -957.03 Thousand CAD | 61.56% |
| 2012 | -1.61 Million CAD | -282.76% |
| 2011 | 24.81 Million CAD | 1412.61% |
| 2010 | 2 Million CAD | 97.05% |
| 2009 | -1.33 Million CAD | -153.45% |
| 2008 | -7.99 Million CAD | 96.49% |
| 2007 | -38.76 Million CAD | 9.19% |
| 2006 | -28.61 Million CAD | -125.76% |
| 2005 | -12.77 Million CAD | 18.12% |
| 2004 | -15.42 Million CAD | -158.26% |
| 2003 | -5.94 Million CAD | -42.96% |
| 2002 | -4.16 Million CAD | -9.07% |
| 2001 | -3.81 Million CAD | -18.67% |
| 2000 | -3.21 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 582 Thousand CAD | 156.18% |
| 2024 Q2 | -556 Thousand CAD | -195.53% |
| 2023 Q2 | 876 Thousand CAD | 1.04% |
| 2023 FY | - CAD | -60.89% |
| 2023 Q1 | 867 Thousand CAD | -36.48% |
| 2023 Q3 | 108 Thousand CAD | -87.67% |
| 2023 Q4 | -1.04 Million CAD | -1066.67% |
| 2022 Q4 | 1.36 Million CAD | 28.41% |
| 2022 Q3 | 1.06 Million CAD | 223.32% |
| 2022 Q2 | -862 Thousand CAD | -227.51% |
| 2022 Q1 | 676 Thousand CAD | -65.12% |
| 2022 FY | - CAD | 30.88% |
| 2021 Q2 | 268 Thousand CAD | 964.52% |
| 2021 Q4 | 1.93 Million CAD | 393.13% |
| 2021 Q1 | -31 Thousand CAD | 98.45% |
| 2021 FY | - CAD | 156.96% |
| 2021 Q3 | 393 Thousand CAD | 46.64% |
| 2020 Q3 | 149 Thousand CAD | 169.3% |
| 2020 FY | - CAD | 48.73% |
| 2020 Q1 | -2.44 Million CAD | 65.76% |
| 2020 Q2 | -215 Thousand CAD | 91.2% |
| 2020 Q4 | -2 Million CAD | -1444.97% |
| 2019 Q1 | -956 Thousand CAD | 31.19% |
| 2019 FY | - CAD | -557.53% |
| 2019 Q2 | 864 Thousand CAD | 190.38% |
| 2019 Q3 | -1.57 Million CAD | -282.29% |
| 2019 Q4 | -7.13 Million CAD | -353.21% |
| 2018 Q3 | 1.22 Million CAD | 328.67% |
| 2018 FY | - CAD | -111.31% |
| 2018 Q1 | -639.19 Thousand CAD | 61.79% |
| 2018 Q4 | -1.38 Million CAD | -213.4% |
| 2018 Q2 | -535.74 Thousand CAD | 16.18% |
| 2017 Q3 | 3.49 Million CAD | -43.95% |
| 2017 FY | - CAD | 74.25% |
| 2017 Q1 | -1.9 Million CAD | -303.35% |
| 2017 Q4 | -1.67 Million CAD | -147.9% |
| 2017 Q2 | 6.23 Million CAD | 427.77% |
| 2016 Q3 | 3.05 Million CAD | 188.34% |
| 2016 Q2 | 1.05 Million CAD | -39.19% |
| 2016 FY | - CAD | 319.18% |
| 2016 Q1 | 1.74 Million CAD | 772.05% |
| 2016 Q4 | 934.74 Thousand CAD | -69.41% |
| 2015 Q2 | 764.8 Thousand CAD | 18.99% |
| 2015 Q4 | 199.85 Thousand CAD | 1423.64% |
| 2015 Q1 | 642.76 Thousand CAD | 0.0% |
| 2015 FY | - CAD | -12.67% |
| 2015 Q3 | 13.11 Thousand CAD | -98.28% |
| 2014 Q3 | 1.64 Million CAD | 303.3% |
| 2014 Q2 | -811.03 Thousand CAD | -227.11% |
| 2014 Q1 | 638.04 Thousand CAD | 392.49% |
| 2014 FY | - CAD | 397.55% |
| 2013 Q2 | -586.43 Thousand CAD | 26.22% |
| 2013 FY | - CAD | 61.56% |
| 2013 Q4 | -218.14 Thousand CAD | 6.18% |
| 2013 Q3 | -232.5 Thousand CAD | 60.35% |
| 2013 Q1 | -794.85 Thousand CAD | -284.35% |
| 2012 Q1 | -19.23 Thousand CAD | -101.37% |
| 2012 Q2 | 23.15 Million CAD | 120486.01% |
| 2012 Q3 | -34.13 Thousand CAD | -100.15% |
| 2012 Q4 | -206.8 Thousand CAD | -505.88% |
| 2012 FY | - CAD | -282.76% |
| 2011 Q2 | 1.15 Million CAD | 212.19% |
| 2011 Q3 | -23.65 Million CAD | -2146.85% |
| 2011 Q4 | 1.4 Million CAD | 105.94% |
| 2011 Q1 | -1.03 Million CAD | 33.21% |
| 2011 FY | - CAD | 1412.61% |
| 2010 Q3 | 549.21 Thousand CAD | 4367.06% |
| 2010 Q4 | -1.54 Million CAD | -380.85% |
| 2010 FY | - CAD | 97.05% |
| 2010 Q1 | -275.6 Thousand CAD | 78.94% |
| 2010 Q2 | -12.87 Thousand CAD | 95.33% |
| 2009 Q2 | -7.53 Million CAD | -401.11% |
| 2009 Q3 | -696.1 Thousand CAD | 90.76% |
| 2009 Q4 | -1.3 Million CAD | -88.02% |
| 2009 FY | - CAD | -153.45% |
| 2009 Q1 | 2.5 Million CAD | -21.09% |
| 2008 Q4 | 3.16 Million CAD | 155.36% |
| 2008 Q3 | 1.24 Million CAD | 154.21% |
| 2008 FY | - CAD | 96.49% |
| 2008 Q1 | 4.67 Million CAD | 132.83% |
| 2008 Q2 | -2.28 Million CAD | -148.95% |
| 2007 Q4 | -14.24 Million CAD | -2.28% |
| 2007 Q2 | -11.77 Million CAD | -53.23% |
| 2007 Q1 | -7.68 Million CAD | -55.23% |
| 2007 FY | - CAD | 9.19% |
| 2007 Q3 | -13.92 Million CAD | -18.32% |
| 2006 Q1 | -2.72 Million CAD | 22.07% |
| 2006 Q4 | -4.94 Million CAD | -24.01% |
| 2006 Q2 | -2.54 Million CAD | 6.77% |
| 2006 Q3 | -3.99 Million CAD | -57.06% |
| 2006 FY | - CAD | -125.76% |
| 2005 Q3 | -3.74 Million CAD | 23.45% |
| 2005 Q4 | -3.49 Million CAD | 6.52% |
| 2005 FY | - CAD | 18.12% |
| 2005 Q1 | -4.79 Million CAD | -32.79% |
| 2005 Q2 | -4.88 Million CAD | -1.87% |
| 2004 Q4 | -3.61 Million CAD | -38.87% |
| 2004 FY | - CAD | -158.26% |
| 2004 Q2 | -2.16 Million CAD | -48.49% |
| 2004 Q3 | -2.6 Million CAD | -20.25% |
| 2004 Q1 | -1.45 Million CAD | -17.77% |
| 2003 FY | - CAD | -42.96% |
| 2003 Q1 | -909.02 Thousand CAD | 25.64% |
| 2003 Q2 | -888.97 Thousand CAD | 2.27% |
| 2003 Q4 | -1.23 Million CAD | -13.07% |
| 2003 Q3 | -1.09 Million CAD | -23.09% |
| 2002 Q3 | -1.19 Million CAD | 0.0% |
| 2002 FY | - CAD | -9.07% |
| 2002 Q4 | -1.22 Million CAD | -2.03% |
| 2001 FY | - CAD | -18.67% |
| 2000 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.68 Million CAD | 147.476% |
| CanadaBis Capital Inc. | 5.67 Million CAD | 77.58% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 77.584% |
| Delivra Health Brands Inc. | 2.35 Million CAD | 45.922% |
| Entourage Health Corp. | -21.39 Million CAD | 105.949% |
| Lifeist Wellness Inc. | -12.76 Million CAD | 109.969% |
| Cannara Biotech Inc. | 17.18 Million CAD | 92.593% |
| PharmaCielo Ltd. | -12.01 Million CAD | 110.592% |
| Rubicon Organics Inc. | 1.94 Million CAD | 34.651% |
| BioSyent Inc. | 9.05 Million CAD | 85.946% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | 204.263% |